Press release from Companies
Published: 2024-02-22 12:47:45
Copenhagen, Denmark, 22 February 2024 - Curasight A/S ("Curasight" or the "Company" – TICKER: CURAS) has prepared and published an information memorandum (the "Information Memorandum") relating to the new issue of shares with preferential rights for the Company's existing shareholders of up to DKK 51.2 million before transaction costs (the "Rights Issue"), which was resolved by the Board of Directors on 13 February 2024. The Information Memorandum is available on the Company's, Nordic Issuing AB's and Redeye AB's respective websites (www.curasight.com, www.nordic-issuing.se, www.redeye.se).
Summary of the Rights Issue Information Memorandum Full terms and conditions for the Rights Issue as well as other information about the Company and further information about subscription commitments, is included in the Information Memorandum. The Information Memorandum is available on the Company's, Nordic Issuing AB's and Redeye AB's respective websites (www.curasight.com, www.nordic-issuing.se, www.redeye.se). Subscription forms will be available on the Company's, Nordic Issuing AB’s, and Redeye AB's respective websites. Timetable for the Rights Issue Advisors Redeye AB is acting as a financial advisor to Curasight. DLA Piper Denmark Advokatpartnerselskab is acting as the legal adviser of Curasight. VP Euronext Securities A/S is the Company’s issuing agent and Nordic Issuing is acting as the settlement agent. For more information regarding Curasight, please contact: Ulrich Krasilnikoff, CEO Phone: +45 22 83 01 60 E-mail: uk@curasight.com
21 February – 5 March 2024
Trading in subscription rights
22 February 2024
Record date for the Rights Issue
22 February 2024
Publication of the Information Memorandum
23 February – 7 March 2024
Subscription period
23 February until the Rights Issue is registered with the Danish Business Authority
Trading in temporary shares
Around 12 March 2024
Estimated publication of the outcome in the Rights Issue